Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease

https://ift.tt/ms2h37D

Dupixent^® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease

from Sanofi - Aventis Groupe https://ift.tt/pW4FtLg
via IFTTT